Students in Arkansas High School's Education Accelerated by Service and Technology Initiative are preparing to head to the ...

A vague 2026 release date for the long-awaited season four of the hit TV show Ted Lasso has been revealed. Ted Lasso first aired in August 2020 and has become a much-loved programme, going on to span ...

This is read by an automated voice. Please report any issues or inconsistencies here. Ted Chen, a familiar face on NBC4 News since 1995, has signed off after 30 years to pursue full-time Christian ...

7 asthma medications: A guide to learn more Asthma is a chronic respiratory condition that affects millions of people of all ages. While there is no cure, modern asthma medications make it possible ...

Rumors are again swirling that Ted Cruz is eyeing the Oval Office, teeing up a potential showdown between the Texas Senator and Vice President JD Vance. Per a Washington Post report, Cruz is seriously ...

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adult and pediatric patients aged ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...

A new option for hard-to-control asthma: The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma. Designed to reduce flare-ups: The injectable ...

What Is Exdensur, and Why Does It Matter? Exdensur (depemokimab) is a new type of ultra long-acting biologic medicine approved by the FDA as an add-on maintenance treatment for severe eosinophilic ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won European regulatory approval for two inflammatory disease indications. The European Medicines Agency's ...